fashion -WSS

fashion

author：hotspot 2025-09-03 03:29:33 - browse：4894

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Criminal prosecution for violating HIPAA: an emerging threat

knowledge

WSS

U.K. decision on ALS drug has neurologists, advocates up in arms

Researchers test human milk's ability to repair gut microbiome

Mass General Brigham physicians react to latest merger step

Addiction experts warn against a second 'war on drugs'

Wearables generate powerful data but its not useful to doctors, yet

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Solving academic medical centers' existential crisis

United colonoscopy coverage change 'may cost lives,' doctors say

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

BioMarin wins approval for gene therapy to treat hemophilia A

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

DIEP, the 'gold standard' of breast reconstruction, is under threat

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Glen Campbell's doctor discusses his public struggle with Alzheimer's

hotspot

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Readers respond to H5N1 and livestock movements, and more

Wearables generate powerful data but its not useful to doctors, yet

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Cytokinetics CEO stresses company can launch heart drug on its own

knowledge

knowledge

Wikipedia

leisure time